Abstract
Kigamicin D is a novel anticancer agent that was identified using a new screening strategy that targets the tolerance of cancer cells to nutrient starvation [1, 2]. Oral administration of kigamicin D was previously described to show a strong antitumor effect in human tumor xenograft models of pancreatic tumors [2]. In this paper we describe that kigamicin D shows the same selective cytotoxicity against normal human cells such as lung fibroblast and prostate stromal cells under nutrient starved condition as against cancer cells. Kigamicin D inhibited tumor cell-induced angiogenesis in a dorsal air sac assay. On the basis of these results we tested other human tumor xenograft models and transplantable syngeneic tumor models in order to determine the spectrum of activity of kigamicin D against various cancers. Kigamicin D showed a weak antitumor effect against LX-1 and DMS-273 lung cancers, but had no effect on DLD-1 colon cancers. When tested against syngeneic tumors, kigamicin D showed a weak antitumor effect against colon26, but showed augmentation of tumor growth on IMC carcinoma at a broad dosage level. Kigamicin D does not show good antitumor activity against human xenograft tumors except pancreatic tumors and murine syngeneic tumors. We found that kigamicin D has excellent antitumor effect specific to pancreatic cancers. Surprisingly, high dosage of kigamicin D increased tumor growth of IMC carcinoma by than 200%. The phenomenon suggests that kigamicin D may cause some immunological response to the tumor.
Similar content being viewed by others
Article PDF
References
Kunimoto S, Lu J, Esumi H, Yamazaki Y, Kinoshita N, Honma Y, Hamada M, Ohsono M, Ishizuka M, Takeuchi T . Kigamicins, novel antitumor antibiotics. I. Taxonomy, isolation, physico-chemical properties and biological activities. J Antibiot 56: 1004–1011 ( 2003)
Lu J, Kunimoto S, Yamazaki Y, Kaminishi M, Esumi H . Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. Cancer Sci 95: 547–552 ( 2004)
O'Brien J, Wilson I, Orton T, Pognan F . Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267: 5421–5426 ( 2000)
Oikawa T, Sasaki M, Inose M, Shimamura M, Kuboki H, Hirano S, Kumagai H, Ishizuka M, Takeuchi T . Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo. Anticancer Res 17: 1881–1886 ( 1997)
Masuda T, Ohba S, Kawada M, Iijima, Ikeda D, Kunimoto S . Augmentation of cellular immunity by kigamicin D. J Antibiot 59: 215–219 ( 2006)
Oikawa T, Shimamura M . Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Eur J Pharmacol 318: 93–96 ( 1996)
Su JD, Mayo LD, Donner DB, Durden DL . PTEN and phosphatidylinositol 3′ kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: Evidence for an effect on the tumor and endothelial compartment. Cancer Res 63: 3585–3592 ( 2003)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Masuda, T., Ohba, S., Kawada, M. et al. Antitumor Effect of Kigamicin D on Mouse Tumor Models. J Antibiot 59, 209–214 (2006). https://doi.org/10.1038/ja.2006.29
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ja.2006.29
Keywords
This article is cited by
-
Augmentation of Cellular Immunity by Kigamicin D
The Journal of Antibiotics (2006)